Abstract
The standard third-line treatment of metastatic colorectal cancer (mCRC) is regorafenib, fruquintinib, or TAS-102. However, the efficacy was not satisfied. We conducted a phase Ib /Ⅱa clinical study to evaluate the safety and efficacy of fruquintinib plus cetuximab in mCRC（TPS151, 2021 ASCO GI） This time we reported the phase Ib dose-escalation study results.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
